Expert Point of View: New Genetic Signature May Help Identify Risk of Relapse in Patients with Completely Resected Early Non–Small Cell Lung Cancer


Get Permission

3.8.38_carbone.jpg

Commenting on the study, David Carbone, MD, PhD, of the Vanderbilt-Ingram Cancer Center, said that the Spanish group studied tumors from patients with completely resected stage I and II NSCLC for gene RNA expression profiles using 41,000 different probes. “Since over one-half of these patients relapse and die from their cancer in spite of complete resection, there is a pressing need for both defining those patients at the greatest risk of relapse for trials of adjuvant therapy, but also potentially avoiding the toxicity of adjuvant therapy in patients with a low risk of relapse,” Dr. Carbone said. “This is a potentially extremely important classifier, which if independently validated, could be the basis of such a test,” he said. Dr. Carbone noted that “It is interesting that the majority of the genes in the classifier are either immune-derived or immunomodulatory, suggesting a potential molecular basis for this observation.” ■

Disclosure: Dr. Carbone reported no potential conflict of interest.


Related Articles

Genetic Signature Identifies Risk of Relapse in Completely Resected Early NSCLC

A new genetic signature identified by Spanish researchers may provide robust and objective information about which patients with completely resected early stage non-small cell lung cancer are at low or high risk of relapse following surgery, according to Florentino Hernando, MD, who presented the...


Advertisement

Advertisement



Advertisement